Drug Trial Radar · NCT03819881
A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy
Last checked: Nov 19, 2026Latest source record: Jan 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 10, 2018
Primary completion
Nov 2019
Study completion Nov 2019
Sponsor
- Lead sponsor
- Siolta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Integrium
- First posted
- Jan 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the safety and tolerability of STMC-103H compared to placebo in allergic subjects who are otherwise healthy.
Conditions
- Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions
STMC-103HBiological
Live bacterial product
PlaceboBiological
Inactive placebo substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with treatment-related adverse events (AEs) assessed as mild, moderate and severe, from baseline to day 29.Time frame: From baseline to day 57
- Incidence of abnormal laboratory test results from baseline to day 29Time frame: From baseline to day 29
- Change in blood pressure from baseline to day 57Time frame: From baseline to day 57
- Change in respiration rate from baseline to day 57Time frame: From baseline to day 57
- Change in heart rate from baseline to day 57Time frame: From baseline to day 57
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Bensch Clinical Research LLC
Stockton, California · Recruiting
Orange County Research Center
Tustin, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.